Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In a retrospective multicenter cohort study, this research observed that baricitinib was effective and well-tolerated in treating adult patients with alopecia areata, including those with severe cases, showing promise in improving outcomes over a 12-month period with manageable side effects.

This article discusses alopecia areata and lichen planopilaris, providing a review of their clinical characteristics and reporting no new research findings; the authors underscore the potential progression and distinctive features of each condition.

This study found that 1% anthralin ointment effectively promoted hair growth in children with chronic, severe alopecia areata, showing complete or partial responses in 70% of participants over 12 months, without serious adverse events.

This study found that after 15 months of treatment with ritlecitinib, patients with alopecia areata and less than 95% initial hair loss experienced significant hair regrowth, though those with more extensive hair loss showed more variable improvement.

This narrative review reports that baricitinib, a first-generation JAK inhibitor, has shown effectiveness in treating alopecia areata and atopic dermatitis and holds promise for other chronic dermatoses, marking a significant advancement in dermatological immunotherapy according to the summarized findings.

This review assessed evidence on laser therapies for alopecia areata, reporting that the 308-nm excimer laser showed hair regrowth in several studies, while more research is needed for other laser types.

This review synthesizes current evidence on therapies for dissecting cellulitis of the scalp, noting that biologics show promise for treatment-resistant cases, though systemic retinoids remain the first-line therapy.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

This case report describes a 60-year-old male with vitamin A toxicity leading to severe liver disease and symptoms that resolved following liver transplantation, suggesting transplantation as a treatment option for noncirrhotic portal hypertension when symptoms do not improve after stopping vitamin A.

In this case report, significant improvements in a 58-year-old male with severe refractory myasthenia gravis and concurrent alopecia areata were observed following a cortisone taper, suggesting a potential therapeutic role, especially after thymectomy.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

In this study, tofacitinib monotherapy was effective in achieving hair regrowth in over half of Korean patients with moderate-to-severe and refractory alopecia areata, though treatment discontinuation typically led to hair loss recurrence.

This review discusses botulinum toxin's experimental off-label uses in dermatology, highlighting promising results but emphasizing the need for more clinical trials to confirm efficacy and safety.

This review examines existing research and clinical trials on the use of dupilumab for various skin, respiratory, and gastrointestinal disorders, but it reports no new clinical findings.

This study found that both ciclosporin A and topical therapy were effective in reducing alopecia and scaling in dogs with idiopathic sebaceous adenitis, with evidence suggesting improved outcomes when both treatments are combined.

This case series reports successful treatment of refractory folliculitis decalvans using surgical excision with second-intention healing and guarded high-tension suturing, resulting in long-term remission without recurrence over a 10–24 month follow-up period.

This review compiles current information about Eclipta prostrata, traditional uses, and its promising pharmacological properties, like hepatoprotective and anti-inflammatory effects, but emphasizes that more research is needed to fully understand its mechanisms and ensure safety for clinical application.

This study found that a dopamine-methacrylated hyaluronic acid hydrogel enhances the efficacy of adipose-derived stem cells in promoting skin regeneration, potentially involving the Notch signaling pathway.

In this study, researchers found that a specific genetic variant in the INSR gene is linked to severe insulin resistance and hyperandrogenemia in type A insulin resistance syndrome, suggesting the benefit of exon sequencing for accurate diagnosis and treatment.

This study found higher serum prolactin levels in patients with psoriasis, vitiligo, and alopecia areata compared to controls, and prolactin levels correlated with disease severity in psoriasis and alopecia areata but not vitiligo.

In this study, injection of cross-linked hyaluronic acid into the upper eyelid significantly improved the appearance of sunken and hollowed eyes in participants over a period of more than one year, with follow-ups at two weeks and three months.

This study concluded that combining systemic cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata while maintaining safe cyclosporine A levels in the blood.

This study demonstrated that intramuscular corticosteroids were effective for severe alopecia areata, with significant hair regrowth in 80.2% of patients, though a high relapse rate was noted post-treatment. Nail involvement and disease duration over six months negatively impacted outcomes.

In this case report, researchers describe a 44-year-old woman with refractory patch alopecia areata achieving complete hair regrowth using a multi-modal approach of systemic and topical cholecalciferol with microneedling, although systemic vitamin D repletion remains a significant confounder.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

In this study, combination therapy with cyclosporine and PUVA for severe alopecia areata resulted in a majority of patients showing only fair to poor responses, though some improvements were noted.

This review discusses the use of topical and intralesional corticosteroids for treating alopecia areata, highlighting their efficacy and safety but noting recurrence and pain as limitations; no new clinical results are reported.

In this case series, four African American women with treatment-resistant central centrifugal cicatricial alopecia showed scalp itch relief and significant hair regrowth after using a new botanical formula for 8 weeks to 1 year, with no adverse effects reported.

This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.